- Home
- GNTA vs INMB Comparison
GNTA vs INMB Comparison
Compare GNTA & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTA
- INMB
- Stock Information
- Founded
- GNTA 2014
- INMB 2015
- Country
- GNTA Italy
- INMB United States
- Employees
- GNTA N/A
- INMB N/A
- Industry
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- GNTA Health Care
- INMB Health Care
- Exchange
- GNTA Nasdaq
- INMB Nasdaq
- Market Cap
- GNTA 64.3M
- INMB 68.9M
- IPO Year
- GNTA 2021
- INMB 2019
- Fundamental
- Price
- GNTA $3.44
- INMB $1.87
- Analyst Decision
- GNTA Strong Buy
- INMB Buy
- Analyst Count
- GNTA 1
- INMB 4
- Target Price
- GNTA $25.00
- INMB $9.53
- AVG Volume (30 Days)
- GNTA 9.1K
- INMB 754.9K
- Earning Date
- GNTA 01-01-0001
- INMB 10-30-2025
- Dividend Yield
- GNTA N/A
- INMB N/A
- EPS Growth
- GNTA N/A
- INMB N/A
- EPS
- GNTA N/A
- INMB N/A
- Revenue
- GNTA N/A
- INMB $50,000.00
- Revenue This Year
- GNTA N/A
- INMB $142.83
- Revenue Next Year
- GNTA N/A
- INMB $14,780.90
- P/E Ratio
- GNTA N/A
- INMB N/A
- Revenue Growth
- GNTA N/A
- INMB N/A
- 52 Week Low
- GNTA $2.74
- INMB $1.81
- 52 Week High
- GNTA $7.28
- INMB $11.64
- Technical
- Relative Strength Index (RSI)
- GNTA 43.44
- INMB 31.44
- Support Level
- GNTA $3.41
- INMB $1.86
- Resistance Level
- GNTA $3.68
- INMB $2.00
- Average True Range (ATR)
- GNTA 0.29
- INMB 0.13
- MACD
- GNTA -0.01
- INMB 0.01
- Stochastic Oscillator
- GNTA 16.54
- INMB 4.44
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.